@article{ATM22644,
author = {Spencer Hart and Gopal Gupta},
title = {Editorial on “Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer”},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 2},
year = {2018},
keywords = {},
abstract = {Renal cell carcinoma remains a common entity with approximately 65,340 new cases diagnosed in 2018. Given the insidious onset of disease, approximately 25–30% of patients will present with metastatic disease and require systemic therapy (1). Fortunately, the last two decades has seen the development of a number of targeted therapies including mammalian target of rapamycin (mTOR) inhibitors as well as tyrosine kinase inhibitors (TKIs) which are commonly used as first and second line therapies.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/22644}
}